Next Article in Journal
Hybrid Ureteroenteric Anastomosis Is Associated With Lower Stricture Rates in Ileal Conduit Urinary Diversion
Previous Article in Journal
Circulating Tumor DNA (ctDNA) in Kidney Cancer: A Narrative Review
 
 
Société Internationale d’Urologie Journal is published by MDPI from Volume 5 Issue 1 (2024). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Société Internationale d’Urologie.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Oncologic Outcomes of a Novel Mapping Biopsy Technique Before Surgical Excision in the Management of Extramammary Paget Disease

by
Kyle M. Rose
1,*,
Rosalie Zurlo
2,
Roger Li
1,
Gerard Mosiello
3 and
Philippe E. Spiess
1
1
Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA
2
Morsani College of Medicine, University of South Florida, Tampa, FL 33602, USA
3
Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL 33602, USA
*
Author to whom correspondence should be addressed.
Soc. Int. Urol. J. 2023, 4(1), 34-38; https://doi.org/10.48083/LCME5237
Submission received: 17 May 2022 / Revised: 17 May 2022 / Accepted: 19 August 2022 / Published: 18 January 2023

Abstract

:
Objective: To analyze oncologic outcomes of patients with extramammary Paget disease (EMPD) undergoing a novel mapping biopsy before tumor excision (WLE). Methods: We analyzed 19 consecutive patients with EMPD treated with biopsy and/or surgical excision at Moffitt Cancer Center from 2013 to 2021. Biopsy technique, patient demographics, pathology, and oncologic outcomes were analyzed. Results: In total, 19 patients were included in the analysis. Median age at diagnosis was 72. No patients were diagnosed with secondary malignancy during mandatory workup. Of the 17 patients receiving novel mapping biopsy, 8/17 had at least one positive core biopsy site, with a mean of 7% positivity of the total core sites (4/60). Mapping biopsy positive sites helped shape perimeters for wide local excision (WLE) for patients opting for surgical treatment. Although an extensive mapping biopsy was performed, WLE margins were positive in 11/17 patients. Although positive pathologic margins following surgical excision were prominent, only one patient experienced recurrence of EMPD during a median follow-up period of 38 months. Conclusions: We have demonstrated a standardized mapping biopsy before surgical excision in the management of EMPD in men. Despite extensive mapping biopsies, positive surgical margin rates are high, and this may reflect the occult nature of the disease process. Close follow-up is warranted in patients regardless of margin status, but those with positive surgical margins may benefit from more aggressive regimens.

1. Introduction

Extramammary Paget disease (EMPD) is a rare neoplasm presenting in the genital and perianal regions of men and women. It is characterized by a chronic erythematous plaque and is commonly associated with pruritis and pain[1]. The discomfort associated with the lesions often leads to mischaracterization as eczema or fungal infection, which may further delay treatment. Unfortunately, despite standard of care measures, recurrence rates as high as 16% to 61% have been reported[2,3,4,5]. Surgical excision with negative margins is the gold standard in management, but topical and systemic chemotherapy can also be used if there are contraindications to surgery[6].
EMPD is treated by a variety of specialties including urologists, colorectal surgeons, and dermatologists, depending on location and patient access to care. As a result, there is no standardized biopsy or wide local excision (WLE) technique for EMPD to ensure negative resection margins. Dermatologists frequently utilize Mohs micrographic surgery to provide pathological confirmation of negative margins intraoperatively. In contrast, WLE is traditionally employed by urologists and colorectal surgeons, and requires a pre-resection biopsy. In either case, standardization of biopsy and excision technique is lacking.
The establishment of a global strategy for mapping before excision is paramount in the surgical management of EMPD. Herein, we describe a novel standardized technique in the mapping and treatment of EMPD at our institution. Our objective was to determine the efficacy of this mapping technique before excision by analyzing recurrence rates of EMPD, thereby assessing the accuracy of surgical margin delineation.

2. Materials and Methods

After obtaining institutional review board approval, we performed an analysis on patients undergoing surgical excision for EMPD at our facility between 2013 and 2021. For inclusion, patients were required to have had a mapping biopsy and/or WLE. All cases were performed by a single surgeon. All patients underwent mandatory cystoscopy and colonoscopy, which were required to be negative. Patient demographics, clinicopathologic outcomes, and perioperative outcomes were collected. Patient clinical stage was determined using the TNM staging system for EMPD as described by Ohara et al.[7]. Perioperative complications were scored using the modified Clavien-Dindo scale[8].
The technique for mapping biopsy before excision involves 60 total biopsy sites, taken in a clockwise fashion around the lesion. The biopsies are typically 1.5 mm in size, and 5 are taken for each “hour” of the clock face, spaced 1 cm apart. This technique allows the surgical team to clearly demarcate the required tissue needed to achieve a negative margin at the time of WLE. All biopsy specimens were reviewed by a dedicated dermatopathologist.

3. Results

From 2013 to 2021, 19 patients underwent mapping biopsy followed by WLE. The median age (IQR) at surgery was 72 (66.5 to 76.0). Table 1 details baseline patient characteristics. Of note, 13 (65%) had a history of malignancy before EMPD diagnosis, the most common of which was a dermatologic carcinoma in 12 patients, followed by prostate cancer in 4 patients. Eleven patients (58%) had a past or current history of smoking. Most patients had at least one medical comorbidity, with 14 diagnosed with hypertension, 8 with hyperlipidemia, 7 with CAD, and 7 with BPH.
Three patients were treated with topical chemotherapy before presentation, while 6 patients were treated with topical antifungals due to misdiagnosis. Preoperative irritative symptoms were reported in 9 patients (47%) at a median (IQR) duration of 2.5 (1.0 to 3.0) years, and included erythema in 17 (89%), itching in 10 (53%), pain in 8 (42%), and drainage in 2 (11%). EMPD occurred in the scrotum-alone in 8 (42%), the perineum in 1 (5%), the groin in 3 (16%), the penis in 2 (11%), and was multifocal in 6 (32%).
Seventeen patients received mapping biopsy, and 2 had shave biopsies. Two patients decided against surgical excision of lesion after biopsy, opting for conservative monitoring. Eight mapping biopsies (47%) were positive for EMPD in at least one core, with an average of 7% of cores positive (4/60). Mapping biopsy results were used to delineate WLE borders, and negative results typically indicated a smaller resection site. Of the 17 patients undergoing surgical excision, 16 had WLE. For wound closure, 8 patients required split thickness skin graft (STSG), in 3, local tissue mobilization was used to assist in closure, 2 patients required creation of a thigh flap, and in 1 case, primary re-approximation was used (Figure 1).
All patients were staged as primary pT1 EMPD on final pathology. Margins were positive in 65% of lesions (11/17). Of the 13 patients with immunohistochemistry staining, Ck7 was positively stained in 10 cases (77%). Lymphovascular and adnexal invasion were uncommon, both occurring in 3 of 7 patients. The median follow-up for the cohort was 14 months, during which time 1 patient experienced recurrence with osseous metastasis 6 years following WLE, and is currently undergoing chemoradiation therapy. During follow-up, there was 1 death of unrelated etiology.
Complications occurred in 5 patients (29%), all related to wound healing. There were 2 episodes of wound dehiscence, one episode of skin necrosis requiring debridement, one episode of tension discomfort requiring repeat STSG, and one episode of prolonged wound healing with abnormal drainage. Table 2 illustrates the size of excised lesions in patients with and without wound complications, for which there were no differences between groups.

4. Discussion

In this series, we describe a standardized mapping biopsy process for EMPD. Our central finding is the high positive WLE margin rate despite extensive preoperative punch biopsy mapping. While surgical excision with negative resection margins remains the gold standard treatment in EMPD, barriers to achieving negative margins include the multifocal nature of this disease process, as well as the presence of skip lesions. Positive margins have been identified as risk factors for tumor invasion, recurrence, and metastasis in prior EMPD series[9,10]. In a recently published review by Leong and Chung, the investigators complied composite scores for recurrence based on margin status at the time of excision. Patients with positive margins at WLE demonstrated a higher recurrence rate of 48% versus 15% in those with negative margins. Similarly, the authors compared composite scores of WLE and Mohs micrographic surgery, and identified Mohs as having a lower positive margin rate (18% versus 33%). The use of Mohs surgery may be a limiting factor depending on resources available to certain institutions, but microdissection and pathologic review in real time appear to be beneficial. Additional surgical augmentations include the use of intraoperative frozen sections, which has demonstrated a higher negative margin rate (92% versus 26%)[11]. Additionally, surgeons have utilized fluorescein to augment visualization during excision, which has a 97% positive predictive value and 99.9% negative predictive value[12]. Both of these tools add value in the surgeon’s armamentarium.
The high positive surgical margin rate in our series is unfortunately a common, with previous studies reporting rates as high as 40% to 60% after surgical excision[13,14,15,16,17]. However, while recurrence rates are higher in margin-positive patients, the direct impact on cancer specific survival is less clear, especially in the non-invasive malignancy setting. In a survival analysis using the Surveillance, Epidemiology, and End Results (SEER) program, worse survival was associated with increased age and male sex, and in patients who did not receive surgery as primary therapy, especially those who had received radiotherapy[18]. A similar SEER study performed by Herrel and colleagues reported an overall survival of 60% at 120 months post diagnosis[19]. The authors identified that patient age and presence of EMPD in the perianal and truncal regions portended a worse prognosis[19]. However, it is important to note the limitations of these 2 large-sample studies, in that the SEER database does not allow for analysis by margin status. Alternatively, tumor invasion was identified as a significant contributor to survival, as described in the study by Hegarty et al. of 20 patients, in which patients with invasive EMPD demonstrated a lower survival rate of 14.5 months versus 55 months in those with intra-epidermal adenocarcinoma[9].
Our findings suggest that positive surgical margins may not correlate as strongly with recurrence as previously thought. The presence of positive surgical margins does place the patient in a higher risk group, which prompts the surgical team to escalate outpatient follow-up and surveillance. In clinical practice, this could include more frequent examinations, repeat biopsies for recurrent disease, and photograph documentation. The novel mapping biopsy and WLE in our study were performed by a single surgeon to improve uniformity and consistency. Importantly, surgeons should be aware of the potential for wound complications following WLE, which occurred in 5 patients in our series.
Limitations of our study include its retrospective natur e, presenting the potential for selection bias among patients with localized disease. The novel mapping biopsy and WLE utilized in our study was performed by a single surgeon to improve uniformity and consistency. Additionally, our patients were exclusively male, and therefore extrapolation of our findings to the gynecologic field should be limited. Further, the median follow-up in our cohort was relatively short at 14 months. Long-term follow-up data are needed to solidify the relationship between positive surgical margins and disease recurrence. Due to the rarity of this disease process, large-scale randomized trials will be unlikely to accrue, and thus there is a need for uniform mapping biopsies and surgical techniques, as previously described.

5. Conclusions

In this study, we have demonstrated a standardized mapping biopsy before surgical excision in the management of EMPD in men. Despite extensive mapping biopsies, positive surgical margin rates are high, and this may reflect the occult nature of the disease process. Close follow-up is warranted in patients regardless of margin status, but those with positive surgical margins may benefit from more aggressive regimens. Long-term follow-up is needed to determine the impact of microscopically positive margins on disease specific survival, which will aid the surgical team in determining aggressiveness of resection.

Conflicts of Interest

None declared.

References

  1. McDaniel, B.; Brown, F.; Crane, J.S. Extramammary Paget disease. In: StatPearls. Treasure Island (FL)2022 Jan. Available online: https://pubmed.ncbi.nlm.nih.gov/29630276/ (accessed on 12 November 2022).
  2. Hendi, A.; Brodland, D.G.; Zitelli, J.A. Extramammary Paget’s disease: Surgical treatment with Mohs micrographic surgery. J. Am. Acad. Dermatol. 2004, 51, 767–773. [Google Scholar] [CrossRef] [PubMed]
  3. Lee, K.Y.; Roh, M.R.; Chung, W.G.; Chung, K.Y. Comparison of Mohs micrographic surgery and wide excision for extramammary Paget’s disease: Korean experience. Dermatol. Surg. 2009, 35, 34–40. [Google Scholar] [CrossRef] [PubMed]
  4. Pierie, J.P.; Choudry, U.; Muzikansky, A.; Finkelstein, D.M.; Ott, M.J. Prognosis and management of extramammary Paget’s disease and the association with secondary malignancies. J. Am. Coll. Surg. 2003, 196, 45–50. [Google Scholar] [CrossRef] [PubMed]
  5. Wong, D.S.-Y.; Ko, L.W.-L.; Cheung, T.-H. Extramammary Paget’s disease: Surgical control from the plastic surgery perspective. Surg. Pract. 2016, 20, 110–113. [Google Scholar] [CrossRef]
  6. NIH, National Center for Advancing Translational Sciences. Extramammary Paget disease. 2021. Available online: https://rarediseases.info.nih.gov/diseases/4192/extramammary-paget-disease (accessed on 17 September 2021).
  7. Ohara, K.; Fujisawa, Y.; Yoshino, K.; Kiyohara, Y.; Kadono, T.; Murata, Y.; et al. A proposal for a TNM staging system for extramammary Paget disease: Retrospective analysis of 301 patients with invasive primary tumors. J. Dermatol. Sci. 2016, 83, 234–239. [Google Scholar] [CrossRef] [PubMed]
  8. Mitropoulos, D.; Artibani, W.; Biyani, C.S.; Bjerggaard Jensen, J.; Roupret, M.; Truss, M. Validation of the Clavien-Dindo grading system in urology by the European Association of Urology Guidelines Ad Hoc Panel. Eur. Urol. Focus 2018, 4, 608–613. [Google Scholar] [CrossRef] [PubMed]
  9. Hegarty, P.K.; Suh, J.; Fisher, M.B.; Taylor, J.; Nguyen, T.H.; Ivan, D.; Prieto, V.G.; et al. Penoscrotal extramammary Paget’s disease: The University of Texas M. D. Anderson Cancer Center contemporary experience. J. Urol. 2011, 186, 97–102. [Google Scholar] [CrossRef]
  10. Leong, J.Y.; Chung, P.H. A primer on extramammary Paget’s disease for the urologist. Transl. Androl. Urol. 2020, 9, 93–105. [Google Scholar] [CrossRef]
  11. Yang, W.J.; Kim, D.S.; Im, Y.J.; Cho, K.S.; Rha, K.H.; Cho, N.H.; et al. Extramammary Paget’s disease of penis and scrotum. Urology 2005, 65, 972–975. [Google Scholar] [CrossRef] [PubMed]
  12. Misas, J.E.; Cold, C.J.; Hall, F.W. Vulvar Paget disease: Fluorescein-aided visualization of margins. Obstet. Gynecol. 1991, 77, 156–159. [Google Scholar]
  13. Fanning, J.; Lambert, H.C.; Hale, T.M.; Morris, P.C.; Schuerch, C. Paget’s disease of the vulva: Prevalence of associated vulvar adenocarcinoma, invasive Paget’s disease, and recurrence after surgical excision. Am. J. Obstet. Gynecol. 1999, 180 Pt 1, 24–27. [Google Scholar] [CrossRef]
  14. Marchesa, P.; Fazio, V.W.; Oliart, S.; Goldblum, J.R.; Lavery, I.C.; Milsom, J.W. Long-term outcome of patients with perianal Paget’s disease. Ann. Surg. Oncol. 1997, 4, 475–480. [Google Scholar] [CrossRef]
  15. Sarmiento, J.M.; Wolff, B.G.; Burgart, L.J.; Frizelle, F.A.; Ilstrup, D.M. Paget’s disease of the perianal region--an aggressive disease? Dis. Colon Rectum. 1997, 40, 1187–1194. [Google Scholar] [CrossRef]
  16. Yugueros, P.; Keeney, G.L.; Bite, U. Paget’s disease of the groin: Report of seven cases. Plast. Reconstr. Surg. 1997, 100, 336–339. [Google Scholar] [CrossRef]
  17. Zollo, J.D.; Zeitouni, N.C. The Roswell Park Cancer Institute experience with extramammary Paget’s disease. Br. J. Dermatol. 2000, 142, 59–65. [Google Scholar] [CrossRef]
  18. Yao, H.; Xie, M.; Fu, S.; Guo, J.; Peng, Y.; Cai, Z.; et al. Survival analysis of patients with invasive extramammary Paget disease: Implications of anatomic sites. BMC Cancer 2018, 18, 403. [Google Scholar] [CrossRef]
  19. Herrel, L.A.; Weiss, A.D.; Goodman, M.; Johnson, T.V.; Osunkoya, A.O.; Delman, K.A.; et al. Extramammary Paget’s disease in males: Survival outcomes in 495 patients. Ann. Surg. Oncol. 2015, 22, 1625–1630. [Google Scholar] [CrossRef] [PubMed]
Figure 1.
Figure 1.
Siuj 04 00034 g001
Table 1. Clinical characteristics of patients before mapping biopsy.
Table 1. Clinical characteristics of patients before mapping biopsy.
Siuj 04 00034 i001
Table 2. Postoperative wound issue and size of primary lesion.
Table 2. Postoperative wound issue and size of primary lesion.
Siuj 04 00034 i002
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Rose, K.M.; Zurlo, R.; Li, R.; Mosiello, G.; Spiess, P.E. Oncologic Outcomes of a Novel Mapping Biopsy Technique Before Surgical Excision in the Management of Extramammary Paget Disease. Soc. Int. Urol. J. 2023, 4, 34-38. https://doi.org/10.48083/LCME5237

AMA Style

Rose KM, Zurlo R, Li R, Mosiello G, Spiess PE. Oncologic Outcomes of a Novel Mapping Biopsy Technique Before Surgical Excision in the Management of Extramammary Paget Disease. Société Internationale d’Urologie Journal. 2023; 4(1):34-38. https://doi.org/10.48083/LCME5237

Chicago/Turabian Style

Rose, Kyle M., Rosalie Zurlo, Roger Li, Gerard Mosiello, and Philippe E. Spiess. 2023. "Oncologic Outcomes of a Novel Mapping Biopsy Technique Before Surgical Excision in the Management of Extramammary Paget Disease" Société Internationale d’Urologie Journal 4, no. 1: 34-38. https://doi.org/10.48083/LCME5237

Article Metrics

Back to TopTop